Lung Cancer Considered

This episode of Lung Cancer Considered covers lung cancer in India and brings awareness about its first and largest advocacy group in the nation. To learn more about Lung Connect India, key members of the team will share how the organization began and the work they have done to improve the care of patients with lung cancer in the region.

Guest:
Vandana Mahajan, Lead Counselor for Lung Connect India, brings a unique and inspiring voice shaped by her dedication to supporting patients and families affected by lung cancer, and her commitment to driving conversations that matter from prevention and early detection to treatment advances and survivorship.

Sanjeev Sharma, the Director & CEO of Lung Connect India, an initiative dedicated to improving awareness, access, and advocacy in lung cancer care. With a strong commitment to patient-centered innovation, he works to bridge gaps between patients, caregivers, clinicians, and policymakers, advancing meaningful dialogue and practical solutions to improve lung cancer outcomes

As part of IASLC’s ongoing podcast series in world languages, Dr. Chul Kim moderates a discussion in Korean with Dr. Beung-Chul Ahn and Dr. Hyein Jeon. The session focuses on the clinical management of EGFR-mutant non-small cell lung cancer (NSCLC) through a case-based discussion.

Guests:

In this episode, recorded in Mandarin, host Dr. Chunxia Su leads a discussion about early stage and preoperative care for patients with NSCLC with an EGFR mutation.

Guests:

Wenzhao Zhong, Deputy Prensendent of Guangdong Provincial People's Hospital, Director of the Cancer Institute, Guangdong Provincial People's Hospital

Jie Hu， Deputy director, Department of Respiratory Medicine, Shanghai Geriatric Medical Center，Zhongshan Hospital, Fudan University

Min Fan M D， Deputy Director , Department of Radiation Oncology, Fudan University Shanghai Cancer Center

In this episode of Lung Cancer Considered, host Dr. Narjust Florez conducts three mock molecular tumor boards with Dr. Misako Nagasaka and Dr. Biagio Ricciuti, live from the Targeted Therapies of Lung Cancer (TTLC) 2026 conference. The discussion addresses the question, “How do we get the right molecular answer, at the right time, for the right patient?”

Guests:

Misako Nagasaka, MD, PhD
Associate Clinical Professor
University of California, Irvine

Biagio Ricciuti, MD, PhD
Thoracic Medical Oncologist, Dana-Farber Cancer Institute
Faculty, Harvard School of Medicine

In this episode of Lung Cancer Considered, host Dr. Narjust Florez and guest Dr. Sam Rosner examine controversies around antibody-drug conjugates (ADCs) live from the 2026 Targeted Therapies of Lung Cancer (TTLC) conference.

Guest:

Sam Rosner, MD
Assistant Professor of Medicine, University of Maryland School of Medicine
Thoracic Medical Oncologist, University of Maryland Marlene and Stewart Greenebaum Comprehensive Cancer Center